Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 312

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Screening for liver cancer: results of a randomised controlled trial in Qidong, China

Chen, J-G, Parkin, D M, Chen, Q-G, Lu, J-H, Shen, Q-J, Zhang, B-C, Zhu, Y-R·2003·Journal of Medical Screening

Abstract

Objectives: To investigate the effectiveness of screening for liver cancer in reducing mortality from the disease in a high-risk population in China. Setting: A randomised controlled trial was carried out among men aged 30-69 who were chronic carriers of hepatitis-B virus (HBsAg positive) during the period 1989-1995 in Qidong county, Jiangsu Province, China. Methods: 5581 HBsAg carriers were identified by population screening and randomly assigned to a screening group (group A, 3712 men), and controls (group B, 1869 men). Screening was planned to be six monthly alpha-fetoprotein (AFP) assays, with follow-up of subjects having an abnormal (≥20 μg/l) test. All subjects were followed up for liver cancer and/or death until 31 December 1995. Results: The overall sensitivity and specificity of the programme was 55.3% and 86.5%, respectively; in subjects who complied with all scheduled screening tests, the values were 80.0% and 80.9%. Three hundred and seventy-four primary liver cancer (PLC) cases were diagnosed. The percentage of cases in stage I was significantly higher in group A (29.6%) than in group B (6.0%). The one-, three-, and five-year relative survival rates were 23.7%, 7.0%, and 4.0% in group A, and 9.7%, 4.0%, and 4.1% in group B respectively, with no difference in five-year survival between the groups. The mortality rate in the screened group (1138 per 100,000 person-years) was not significantly different from that in the controls (1114 per 100,000). A Poisson regression model showed that the probability of death (rate ratio) in the screening group was 0.83 (95% CI 0.68-1.03) relative to the control group. Conclusions: Screening with AFP resulted in earlier diagnosis of liver cancer, but the gain in lead time did not result in any overall reduction in mortality, because therapy for the patients found by screening was ineffective. Further studies using improved methods of screening, diagnosis and treatment are indicated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1258/096914103771773320

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 312

Metadata

Authors
Chen, J.-G., Parkin, D. M., Chen, Q.-G., Lu, J.-H., Shen, Q.-J., Zhang, B.-C., & Zhu, Y.-R.
Venue
Journal of Medical Screening
Published
2003-12-01
Volume
10
Issue
4
Pages
204-209
ISSN
  • 0969-1413 (ISSN-L)
  • 1475-5793
OpenAlex
W2149634277
Cited by
312
References
1
FWCI
2.45
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Screening for liver cancer: results of a randomised controlled trial in Qidong, China. https://app.cochat.ai/papers/10.1258/096914103771773320
The paper
Chen, J.-G., Parkin, D. M., Chen, Q.-G., Lu, J.-H., Shen, Q.-J., Zhang, B.-C., & Zhu, Y.-R. (2003). Screening for liver cancer: results of a randomised controlled trial in Qidong, China. Journal of Medical Screening. https://doi.org/10.1258/096914103771773320

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.